Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...

The program is examining the effectiveness of a protocol meant to ensure safety for pilots and air traffic controllers on ...

Whatever the outcome of the countering lawsuits, it will be a challenging period for PBMs, given the FTC's actions on alleged ...

Lija Greenseid handed Minnesota Gov. Tim Walz an empty vial of insulin that her 13-year-old daughter had painted gold.

We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...

Once a top-performing stock thanks to its role in developing the first Covid-19 vaccine, Pfizer has seen its share price drop by nearly half from its 2021 peak.

Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer and wants the struggling drugmaker to make ...

Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filing in the gaps.

Eli Lilly & Co. closed $85.37 below its 52-week high ($972.53), which the company reached on August 22nd.